Ubs Asset Management Americas Inc Syndax Pharmaceuticals Inc Transaction History

Ubs Asset Management Americas Inc

$446 Billion
Q3 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 134,261 shares of SNDX stock, worth $2.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,261

Previous 256,138 47.58%

Holding current value

$2.23 Million

Previous $2.4 Million 13.92%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$8.73 - $17.04 $1.06 Million - $2.08 Million	-121,877 Reduced 47.58%	134,261 $2.07 Million
Q2 2025 Aug 14, 2025	BUY	$8.9 - $14.15 $493,433 - $784,504	55,442 Added 27.62%	256,138 $2.4 Million
Q1 2025 May 19, 2025	BUY	$12.29 - $16.38 $376,024 - $501,162	30,596 Added 17.99%	200,696 $2.47 Million
Q4 2024 Feb 14, 2025	BUY	$12.52 - $21.81 $408,815 - $712,161	32,653 Added 23.76%	170,100 $2.25 Million
Q3 2024 Nov 14, 2024	SELL	$17.93 - $24.81 $285,320 - $394,801	-15,913 Reduced 10.38%	137,447 $2.65 Million

Q2 2024 Aug 13, 2024	BUY	$18.82 - $23.79 $1.06 Million - $1.34 Million	56,527 Added 58.38%	153,360 $3.15 Million
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $74,227 - $92,530	3,766 Added 4.05%	96,833 $2.3 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $186,841 - $355,474	16,404 Added 21.4%	93,067 $2.01 Million
Q3 2023 Nov 13, 2023	BUY	$14.52 - $21.77 $333,684 - $500,296	22,981 Added 42.81%	76,663 $1.11 Million
Q1 2023 May 15, 2023	SELL	$20.66 - $28.98 $91,172 - $127,888	-4,413 Reduced 7.6%	53,682 $1.13 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $305,306 - $388,142	14,792 Added 34.16%	58,095 $1.48 Million
Q3 2022 Nov 14, 2022	SELL	$18.51 - $24.79 $54,678 - $73,229	-2,954 Reduced 6.39%	43,303 $1.04 Million
Q2 2022 Aug 12, 2022	BUY	$13.64 - $19.48 $100,731 - $143,859	7,385 Added 19.0%	46,257 $889,000
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $52,706 - $75,240	-3,800 Reduced 8.91%	38,872 $742,000
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $57,504 - $107,896	4,285 Added 11.16%	42,672 $732,000
Q1 2021 May 14, 2021	BUY	$19.28 - $24.59 $234,965 - $299,678	12,187 Added 46.52%	38,387 $858,000
Q4 2020 Mar 01, 2021	BUY	$15.1 - $26.44 $395,620 - $692,728	26,200 New	26,200 $582,000

Others Institutions Holding SNDX

# of Institutions

253

Shares Held

99.8M

Call Options Held

1.41M

Put Options Held

737K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $940M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Syndax Pharmaceuticals Inc Transaction History